BGM Associates

DuChemBio Co. Ltd., advised by BGM Associates, has signed a material transfer and clinical supply agreement for [18F] PI-2620 Tau PET Tracer with Life Molecular Imaging

20/8/2021

DuChemBio Co., Ltd. and Life Molecular Imaging (LMI) have recently announced the signing of a Material Transfer & Clinical Supply Agreement for LMI’s next generation Tau PET Tracer PI-2620.

PI-2620 is an investigational Tau PET agent currently in late stage clinical development by LMI with excellent characteristics and diagnostic performance for the in-vivo assessment of Tau Pathology in Alzheimer's Disease (AD) and other tauopathies by means of hybrid PET scanners.

Under the terms of the Agreement, DuChemBio, who operates the largest radiopharmacy network for a GMP-standard manufacturing of Nuclear Medicine probes for PET imaging in South Korea, has been granted a license to manufacture and supply PI-2620 clinical trial doses in South Korea.

Full Press Release

EQT Infrastructure, advised by BGM Associates, has signed the acquisition of both Meine Radiologie and Blikk to form the leading outpatient radiology and radiotherapy provider in Germany.

15/7/2021

EQT Infrastructure, a long-term investor with an industrial and responsible ownership approach, has recently announced their decision to acquire both Meine Radiologie Holding GmbH from Triton Partners and blikk Holding GmbH from DBAG Fund VII. DBAG will remain a minority shareholder in the combined group.

Meine Radiologie and Blikk were both founded in 2017 and have since then grown to become two highly reputable radiology players in Germany, together employing more than 1,300 people across 65 locations. Both companies are underpinned by long-lasting medical experience from their respective management teams and radiology practices.

Following the closing of the transactions, the combination of the two companies will create a leading radiology and radiotherapy platform in Germany.

BGM Associates has been engaged by EQT Infrastructure to help assess value creation opportunities and synergies between the two companies during the due diligence process.

Full Press Release

DuChemBio Co. Ltd., advised by BGM, has signed an Exclusive Development and Licensing Agreement with Yantai Dongcheng Pharmaceutical Group Co., Ltd. for a diagnostic radiopharmaceutical, [18F]FP-CIT, in China and in the special administrative regions

17/1/2020

YANTAI/SEOUL, December 27th, 2019 – Yantai Dongcheng Pharmaceutical Group Co., Ltd. (YDP) and DuChemBio Co. Ltd. (DCB) have entered into an Exclusive Development and Licensing Agreement for a diagnostic radiopharmaceutical, [18F]FP-CIT, for the People’s Republic of China and the special administrative regions of HongKong and Macao. The diagnostic radiopharmaceutical will be produced by Nanjing-based Dongcheng-AMS, a wholly owned subsidiary of YDP.

Under this Agreement, YDP will assume responsibility for the development and registration of the proprietary PET/CT – tracer in the assigned Territory. Dongcheng-AMS via its network of GMP-standard radiopharmacies, will also manufacture the tracer and commercialize the finished diagnostic product to Nuclear Medicine departments & Molecular Imaging centers across the country.

The Parties have agreed to closely collaborate in the clinical development and scientific promotion of the [18F]FP-CIT tracer to the Nuclear Medicine and Neurology communities.

Press Release (Korean and Chinese)

DuChemBio Co, Ltd., advised by BGM Associates, has signed an exclusive Licensing & Development Agreement with ITM Isotopen Technologien München for Solucin®TRT in South Korea while COMPETE clinical trial sees strong growth in recruitment in the U.S.

19/9/2019

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and DuChemBio Co, Ltd. (DCB), a leading Korean radiopharmaceutical company, recently announced the conclusion of an exclusive licensing and development agreement for Solucin®Targeted Radionuclide Therapy (TRT) in South Korea. The agreement sets out terms concerning the local development, registration and subsequent commercialization by DCB of ITM’s proprietary brand Solucin®for Targeted Radionuclide Therapy (TRT) in South Korea. Solucin®patient doses will be manufactured and exclusively supplied to DCB by ITM.

Within the framework of this collaboration, DCB and ITM plan to initiate a local clinical study for ITM’s Solucin®TRT which is expected to begin recruiting patients in 2020. The study concept is based on ITM’s Phase III clinical trial COMPETE, which has recently seen a considerable increase in patients as a result of strong recruitment in the United States in particular. COMPETE involves 42 leading cancer centers in 12 countries, predominantly in Europe, North America, South Africa and Australia.

Full Press Release

Dongkook Lifescience, supported by BGM Associates, successfully finalized the acquisition of Anseong Supply Center from Bayer Korea

20/8/2019

Dongkook Lifescience, the leading Korean contrast media supplier has acquired Anseong Supply Center from Bayer Korea.

Established in 2017 as a spin-out of Dongkook Pharmaceutical, Dongkook Lifescience is the leading Korean manufacturer and supplier of contrast media for computed tomography (CT) and magnetic resonance imaging (MRI).

Dongkook Lifescience has been advised and supported in this acquisition by BGM Associates.

“We are excited to have successfully finalized this transaction with Bayer. The Anseong manufacturing plant and supply center will enable us to significantly expand our fast-growing contrast media business in Korea and internationally. We are extremely grateful to Prof. Maier and his team of BGM Associates who have supported us throughout the entire process and have facilitated the negotiations with Bayer.” - says Mr. Ki-Ho Cheong, CEO of Dongkook Life Science.

Press Release (Korean)

BGM Associates facilitates the signing of DuChemBio and NihonMedi-Physics Collaboration Agreement to Develop and Commercialize FACBC in South Korea

25/6/2019

DuChemBio Co., Ltd. (DCB), a leading radio-pharmaceutical company in Korea, and Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, recently announced that they have entered into an exclusive agreement to develop, register and commercialize anti-1-amino-3-18F-fluorocyclo-butane-1-carboxylic acid (FACBC) in Korea. FACBC is a radiopharmaceutical for positron emission tomography (PET) imaging of recurrent prostate cancer.

FACBC has been granted marketing authorizations by the Food and Drug Administration (FDA) in the US and the European Medicines Agency (EMA) in EU for imaging of men with suspected prostate cancer recurrence. Prostate cancer patients whose blood test for prostate-specific antigen (PSA) indicate that the cancer may have returned after the initial treatment, such as prostatectomy, usually undergo conventional imaging tests (e.g. CT, MRI, bone scintigraphy). However, the chances to find recurrent cancer lesions in such patients using conventional imaging are relatively low. FACBC-enhanced PET imaging is a proven diagnostic tool for highly optimal management of patients with suspected prostate cancer recurrence.

Full press release

Ascelia Pharma, a specialized oncology company supported by Prof. Hans Maier, is successfully listed on Nasdaq Stockholm Main Market

13/3/2019

Nasdaq Stockholm has today decided to admit the shares of Ascelia Pharma for trading on Nasdaq Stockholm’s Main Market with first day of trading being 13thof March 2019. The additional capital generated from the initial public offering allows Ascelia to fund its global Phase III program for its lead product Mangoral.

Prof. Hans Maier from BGM Associates had joined the company’s board of directors in 2017.

Full Press Release

Prof. Dr. med. Jörg Debatin joins the Advisory Board of BGM Associates

3/9/2018

We are pleased to announce that Prof. Dr. med. Jörg Debatin, MBA has joined the Advisory Board of BGM Associates. Jörg is one of the most well-rounded global health-care leaders with a clear view for the future of medicine. After a most distinguished career as a clinician and researcher in the field of Diagnostic Imaging with tenures at Duke, Stanford, Zürich and Essen, where he served as Chair of the Department of Diagnostic and Interventional Radiology, Jörg opted for a career in Hospital Management. As Medical Director and Chief Executive Officer he oversaw the transformation of the University Medical Center Hamburg-Eppendorf into a showcase of organisational and structural innovation in Germany and beyond.

Jörg subsequently pursued an industrial career as CEO of the blood- and tissue-based diagnostic services provider amedes AG. Until recently he served as the Global Chief Technology and Medical Officer of GE Healthcare.

We very much look forward to working with Jörg in critically important areas such as the digital transformation of healthcare and the future of integrated diagnostics and personalised medicine.

The Board of Trustees of the German Heart Center Berlin (DHZB) elected Prof. Dr. Hans Maier as its fifth President

26/7/2018

L to R: Marcus Polle, Managing Director of DHZB; Prof. Dr. Hans Maier, President of the DHZB Board of Trustees; Prof. Dr. med. Volkmar Falk, Medical Director and Chair of the Executive Board DHZB.

The German Heart Center Berlin performs the entire spectrum of cardiovascular and thoracic operations. It is one of the leading hospitals worldwide for the diagnosis and treatment of cardiovascular diseases.

Full article (in German)

Prof. Dr. Hans Maier elected as the Chairman of the Advisory Board (Kuratorium) of the Fraunhofer MEVIS Institute for Medical Image Computing

20/7/2018

The Fraunhofer MEVIS Institute for Medical Image Computing Advisory Board has elected Prof. Dr. Hans Maier, BGM Associates, as its Chairman and Mr. Walter Märzendorfer, Siemens Healthineers, as its Vice-Chairman.

Fraunhofer MEVIS is a leading developer of medical software solutions for image-supported early detection, diagnosis, and therapy. Embedded in a worldwide network of clinical and academic partners, strong focus is placed on cancer as well as diseases of the circulatory system, brain, breast, liver, and lung. The goal is to detect diseases earlier and more reliably, tailor treatment to each individual, and make therapeutic success more measurable.

Link

<<Previous

NEWS